Welcome to our dedicated page for KONINKLIJKE PHILIPS news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on KONINKLIJKE PHILIPS stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips (PHG) and Southwest Mississippi Regional Medical Center (SMRMC) announced the installation of the first Philips Rembra CT system for acute and high-demand imaging environments in the United States.
The FDA 510(k)-cleared Rembra CT is designed to accelerate scanning and image reconstruction, potentially reducing time patients spend on the table and supporting timely decisions in emergency and trauma care. Throughput testing indicates the system can support up to 270 patient exams per day over a 16-hour day, helping manage growing imaging volumes. With an 85 cm bore, described as largest-in-class, and AI-enabled workflows, the system aims to improve access, positioning and workflow efficiency, expanding advanced diagnostic services for patients in southwest Mississippi.
Royal Philips (PHG) reports that two Philips-led public-private research projects, SYMPHONY and AI FORSchung, have received 2026 ITEA Awards of Excellence for AI-enabled healthcare innovation.
SYMPHONY earned the award for “Exceptional Excellence” after creating a reusable, vendor-neutral reference architecture and demonstrating connected healthcare ecosystems in prostate cancer, aortic aneurysm, atrial fibrillation and multiple sclerosis with clinical partners including Leiden University Medical Center, Amsterdam University Medical Center and Karolinska University Hospital. Philips technology from SYMPHONY to automatically segment and measure vascular structures in medical images has FDA clearance and CE marking, and is available in AV Vascular within the Philips AV Cardiovascular Suite.
AI FORSchung received the innovation award for AI methods that compress Fiber Optic RealShape sensing data more than 20 times while maintaining performance in evaluated datasets.
Royal Philips (PHG) announced a new Philips OneBlade and Red Bull project featuring Red Bull athlete Marco Waltenspiel performing what is described as a world-first wingsuit hot-air balloon slalom over Cappadocia, Turkey.
Waltenspiel jumped from 2,800 meters and flew between seven hot-air balloons at speeds up to 200 km/h, with fellow athlete Marco Fürst filming the flight. The collaboration is presented as a celebration of individuality, self-expression and personal style, linking Waltenspiel’s distinctive moustache and appearance to the Philips OneBlade brand positioning.
Royal Philips (PHG) has launched the Philips Lumea IPL 9900 Pro, described as the first at-home IPL hair removal device with real-time audio feedback and motion guidance.
The device pairs with the Lumea IPL app to track movements and provide live audio and visual coaching during treatment. Philips reports more than 90% hair reduction on legs after three treatments and up to five years of smooth-feeling skin with monthly touch-ups, based on consumer perception data. The Lumea IPL 9900 Pro uses SenseIQ Pro sensor technology to detect skin tone and guide light settings, and it is FDA-cleared. It is available on Amazon’s U.S. store at an MSRP of $699.95 and includes an extended five-year warranty with product registration.
Royal Philips (PHG) introduced the FDA 510(k) cleared and CE marked eV14-2v transvaginal ultrasound transducer, expanding its obstetrics and gynecology portfolio with a single, lightweight probe for a broad range of gynecology and early obstetrics exams.
The eV14-2v is designed to reduce transducer changes by combining enhanced penetration, improved resolution, and a wider field of view. Compared to Philips’ 3D9-3v transducer, it offers a 41.7% increase in penetration, 10% higher 2D resolution, a 15.8% wider field of view, and a 22% lighter design [1]. Built on PureWave crystal technology, it supports detailed visualization for infertility and pelvic pain evaluation and aids detection of fetal abnormalities, with the ability to delineate fetal cardiac chambers from around 13 weeks [2].
The eV14-2v integrates with Philips Collaboration Live for real-time remote consultation, potentially improving access to specialty care in underserved communities. It will be showcased alongside Philips’ Alturion, EPIQ Elite, Lumify, and Flash ultrasound systems at the ISUOG 2026 World Congress.
Philips (NYSE: PHG) and Imricor Medical Systems (ASX: IMR) launched a new Interventional MR (iMR) lab solution for Philips’ 1.5T MRI platform, creating a commercially available configuration for MR-guided cardiac interventions. The integrated solution combines Philips’ Cardiac MR Suite, including SmartHeart AI planning and advanced cardiac imaging, with Imricor’s NorthStar iMR mapping and guidance system, Advantage-MR EP recorder/stimulator, and Vision-MR electrophysiology catheters.
The platform is designed to enable real‑time MR-guided catheter ablation in a radiation‑free environment, allowing visualization of cardiac anatomy, lesion formation, and treatment response during procedures. Built on Philips’ BlueSeal helium-free MRI technology, it aims to reduce siting complexity and support installation closer to cardiology departments. The iMR lab solution is commercially available immediately in CE‑marked markets and, in some configurations, in the U.S., with additional Imricor configurations expected subject to regulatory clearances. According to Philips, the company generated approximately EUR 18 billion in 2025 sales.
Philips (NYSE: PHG) and Imricor Medical Systems (ASX: IMR) launched a new interventional MR (iMR) lab solution built around Philips’ high-performance 1.5T MRI platform and Imricor’s MR-compatible systems and consumables for cardiac interventions. The first commercially available configuration integrates Philips’ Cardiac MR Suite, including SmartHeart AI-powered planning and advanced cardiac imaging, with Imricor’s NorthStar iMR mapping and guidance system, Advantage-MR EP Recorder/Stimulator and Vision-MR electrophysiology catheters.
The solution enables MR-guided cardiac procedures with direct soft-tissue visualization and catheter tracking in a radiation-free iMR lab environment. It uses Philips’ BlueSeal helium-free MRI technology to reduce siting complexity and support installation near cardiology departments. According to Philips, the system is commercially available immediately in CE-marked markets and, in some configurations, in the U.S., and will be showcased at ESC Congress 2026 in Munich.
Philips (NYSE: PHG) has been selected for the U.S. ARPA-H Autonomous Interventions and Robotics (AIR) program and awarded up to US$33.7 million to advance AI-enabled robotic automation for stroke care. Philips will work with Johns Hopkins University, Boston University and clinical collaborator Dr. J Mocco of Weill Cornell Medicine.
The project focuses on remote-assisted and increasingly automated endovascular procedures on the Azurion image-guided therapy platform, developing technologies for robotic device control, endovascular navigation, image-based guidance, workflow automation and remote intervention. According to Philips, these technologies are under development and any future clinical use will depend on applicable regulatory requirements.
Philips (NYSE: PHG) has priced a EUR 650 million fixed-rate EU Green Bond under its EMTN program, consisting of 7.8-year notes due 2034, at 99.655% with a 4.0% coupon and 4.055% yield. The tranche was oversubscribed 2.7 times and is described as the healthcare industry's first EU Green Bond under the new European Green Bond Standard.
According to Philips, an amount equivalent to the gross proceeds will finance taxonomy-aligned economic activities outlined in its European Green Bond Factsheet, supporting its 2030 Impact Ambition. Net debt is not expected to increase, though gross debt will temporarily rise until repayment of a 2027 bond in May 2027. Settlement is scheduled for August 28, 2026, with listing sought on the Luxembourg Stock Exchange. Philips highlights current investment grade ratings of BBB+ (S&P), Baa1 (Moody’s) and BBB+ (Fitch), all with stable outlook.
Philips (NYSE: PHG) and Exor updated their long-term relationship agreement, allowing Exor to increase its shareholding in Philips up to 22% of issued ordinary share capital and voting rights, versus the previous 20% cap. Any stake above 22% remains subject to Philips’ Supervisory Board approval.
Governance arrangements are unchanged, including Exor’s right to nominate one Supervisory Board member. According to Philips, the update reflects Exor’s continued support for Philips’ 2026–2028 plan. Philips reported approximately EUR 18 billion in 2025 sales and about 63,700 employees worldwide.